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INTRODUCTION:  
Oral route of drug administration has wide acceptance 
and hence up to 50-60% of total dosage forms are 
administered orally. Solid dosage forms like tablets and 
capsules though popular but has certain limitations like 
difficulty in swallowing, risk of choking in the throat and 
always require some fluid to consume. This difficulty in 
swallowing or dysphasia is currently affecting 35% of 
general population
1
. Due to this problem, pediatric and 
geriatric patients, tend to avoid taking oral solid dosage 
forms like tablets and capsules due to fear of choking
2
.  
Fast dissolving oral films (FDOFs) are the most 
advanced form of oral solid dosage forms due to more 
flexibility and comfort, improves the efficacy of drugs by 
dissolving within a minute in oral cavity after the contact 
with saliva without chewing and no need of water for 
FDOF’s administration3. It gives quick absorption and 
instant bioavailability of drugs due to high blood flow 
and permeability. FDOFs are useful in patients such as 
pediatric, geriatrics, bedridden, emetic patients, diarrhea, 
sudden episode of allergic attacks, coughing or for those 
who have an active life style
3
.  
Epilepsy is a neurological disorder which requires quick 
management of seizures in order to avoid the risk of 
permanent brain damage
4
. Thus, it is desirable to develop 
fast dissolving films for the anti-epileptic drugs. 
Lamotrigine is a new antiepileptic drug, which acts by 
blocking voltage-dependent sodium channel, and 
reducing the release of excitatory neurotransmitters, 
particularly glutamate and aspartate. It is a bitter drug
5
 
and also has poor aqueous solubility (0.17 mg ml
-1
 at 
25
0
C). Cyclodextrins have been used as increase the 
aqueous solubility of poorly water-soluble drugs and also 
to mask the bitter taste of drugs. Hence, in the present 
study, HP ß CD inclusion complexes were prepared to 
increase the solubility and to mask the bitter taste of 
lamotrigine. Further, these inclusion complexes were 
used to prepare the fast dissolving films with an aim the 
control the epileptic seizures in the shortest possible 
time.     
 MATERIALS: 
Lamotrigine was received as a gift sample from Koppale 
Pharma Pvt Ltd, Hyderabad. HP ß CD was received as a 
gift sample from Gangwal Chemicals Mumbai. HPMC, 
PVA, glycerol, citric acid, aspartame, crosspovidone 
were procured from SD Fine Chemicals, Mumbai. 
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ABSTRACT: 
Objectives: The objectives of the present study is to design and evaluate fast dissolving films of lamotrigine using HP ß CD 
inclusion complexes with an aim to achieve rapid drug release thereby controlling the seizures in the shortest possible time. 
Design: Inclusion complexes of lamotrigine were prepared with hydroxypropyl β cyclodextrin (HP β CD) employing different 
methods to improve the solubility and mask the bitter taste of the drug. Fast dissolving films were prepared by incorporating 
the developed inclusion complexes and using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA) as film 
forming agents and other suitable excipients by solvent casting method.  
Results: Inclusion complexes prepared by ultrasonication method resulted in better solubility and dissolution rate compared to 
other methods studied. The fast dissolving films prepared using inclusion complexes were found to be transparent and smooth 
in texture. The thickness, drug content, % moisture absorption and moisture loss, folding endurance and weight variation was 
found to be uniform. In vitro release profiles were inversely proportional to the polymer and directly proportional to 
superdisintegrant and plasticizer concentration. Optimized formulations (F8 and F12) were subjected for fourier transform 
infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) which revealed the absence of any chemical 
interactions between the excipients of the formulation. The formulations were found to be stable without any significant 
changes during the stability studies carried out as per the ICH guidelines. 
Conclusion: The study revealed the successful development of fast dissolving films of lamotrigine with promising results 
thereby suggesting the possible use of the developed films in the rapid management of epileptic seizures. 
Keywords: Fast dissolving films; epilepsy; lamotrigine; inclusion complex; HPMC; PVA; physico-chemical characterization. 
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METHODS: 
Phase solubility studies
6
: 
Phase solubility studies were carried out in distilled 
water according to the method described by Highuchi 
and Connors. Constant amount of lamotrigine (30 mg) 
that exceeded its solubility was added to 25 ml of 
aqueous solutions of HP β CD in various molar 
concentrations (2-20 mM). Then the suspensions were 
shaken on the rotary shaker at 25ºC for 3 days. The 
samples were filtered, diluted and the concentration of 
lamotrigine was determined spectrophotometrically at 
306 nm. The apparent 1:1 stability constant was 
calculated from the phase solubility graph using the 
following equation, 
Ks =  
Slope
S0  1 − Slope 
 
Where, So is the solubility of lamotrigine in absence of 
HP β CD. 
Preparation of inclusion complexes
7
: Lamotrigine and 
HP β CD complexes were prepared by different methods 
using different molar concentrations of drug and HP β 
CD (1:1 and 1:2).  
Physical Mixture (PM):  
Lamotrigine and HP β CD in the different molar ratios 
were mixed in a mortar for about 15 min with constant 
trituration, passed through sieve No. 80 and stored in a 
dessicator over fused calcium chloride 
Kneading Method (KN): 
Lamotrigine and HP β CD in different molar ratios were 
triturated by adding small quantity of 50% ethanol to get 
slurry like consistency, continued stirring for 1h. Slurry 
was further dried at 25ºC t room temperature for 24 h. 
Pulverized and passed through sieve No. 80 and stored in 
a dessicator over fused calcium chloride. 
Ultrasonication Method: 
Lamotrigine and HP β CD in different molar ratios were 
triturated by adding small quantity of 50% ethanol to get 
slurry like consistency and kept in ultrasonicator for 1hr. 
Slurry was further dried at 25ºC t room temperature for 
24 h. Pulverized and passed through sieve No. 80 and 
stored in a dessicator over fused calcium chloride. 
The prepared inclusion complexes were subjected for 
FT-IR and DSC studies. Dissolution studies for the 
inclusion complexes were also carried out using 900ml 
of 0.1 N HCl as dissolution medium at 50 rpm and 37.0 
±0.5
o
C.   
Preparation of fast dissolving films: 
The fast dissolving films of lamotrigine were prepared 
by solvent casting method
8
 using the prepared inclusion 
complexes with different concentrations of polymers like 
HPMC and PVA, glycerin as plasticizer, citric acid as 
saliva stimulant, aspartame and crosspovidone were used 
as sweetening agent and superdisintegrant respectively. 
Formulation codes and their respective compositions are 
given in the Table: 1. The inclusion complex equivalent 
to 5 mg drug was dissolved in 10ml of distilled water and 
required quantities of the above excipients were added 
and stirred on magnetic stirrer for 1hr. The solution was 
degassed to remove entrapped air by using 
ultrasonicator. The prepared solution was casted on 
mercury employing circular shaped ring of 13.195 cm
2 
and air dried for 24 h. The films were carefully removed 
and cut into required size (2 x 2 cm
2
) to deliver the dose 
equivalent to 5mg per strip. The films were stored in 
aluminium foil and placed in airtight containers for 
further studies. 
 
Table: 1 Formulation of fast dissolving film of lamotrigine 
Code F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
HPMC 200 250 300 200 200 200 200 200 200 200 200 50 100 150 
PVA ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ 150 100 50 
Glycerin 0.1 0.1 0.1 0.2 0.3 0.4 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
CP ̶ ̶ ̶ ̶ ̶ ̶ 2 4 6 ̶ 4 4 4 4 
Citric acid (100mg) Aspartame (5mg) and Pineapple flavor (0.1ml) are constant in all the formulations 
 
Evaluation of fast dissolving films:  
Weight variation test 
9
: 
This test was carried out by taking 2X2 cm
2
 of the film 
cut at three different places from the casted film. The 
weight of each film was taken individually using 
electronic balance. Average of three readings was taken 
for weight variation study. 
Thickness of Film 
10
: 
All the batches were evaluated for thickness by using 
calibrated Vernier caliper. Three readings from all the 
batches were taken and mean thickness was evaluated. 
Drug content uniformity 
11
: 
Drug content of all films was determined by UV-
Spectrophotometric method. For this 2x2cm
2
 film was 
cut and dissolved in 100ml of 0.1 N HCl. The solution 
was filtered and absorbance was recorded at 267.0 nm 
using UV-Spectrophotometer. Drug content was 
calculated using the calibration curve constructed in the 
same media. Triplicate reading were taken and the 
average value was considered as drug content of the 
films. 
Percentage moisture absorption
12
: 
Films were cut into 2x2 cm
2
 (4cm
2
). The moisture 
uptake by the films(n=3) was determined by exposing 
them to an environment of 75% relative humidity 
(saturated solution of potassium sulphate) at room 
temperature for 1 day. The uptake of moisture by the 
Doddayya et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(6):99-106 101 
© 2011-14, JDDT. All Rights Reserved                                                    ISSN: 2250-1177                                            CODEN (USA): JDDTAO 
films was measured and percentage moisture absorption 
was calculated by using the following formulae:  
                                        Final weight – initial weight      
% moisture absorption =     ---------------------------------- x100                                                 
                                                    Initial weight     
Percentage moisture loss
13
: 
Percentage moisture loss was calculated to check the 
integrity of films at dry condition.     Three films 2x2 
cm
2
 was cut out and weighed accurately and kept in 
desiccators containing fused anhydrous calcium 
chloride. After 72 hours the films were removed and 
reweighed. The percentage moisture loss was calculated 
using the formula: 
                                        Final weight – initial weight      
% moisture absorption =    ----------------------------------- x100                                                 
                                                      Initial weight     
Folding endurance 
14
: 
The folding endurance is related to the flexibility of a 
film and it was measured manually by firmly folding 
the films repeatedly through the middle. The number of 
folds on the same crease, required to produce crack in 
the film was noted as the value of folding endurance.  
Surface pH determination 
14
: 
As an acidic or alkaline pH may cause irritation to the 
oral mucosa, it was determined to keep the surface pH 
as close to neutral as possible. A combined pH 
electrode was used for this purpose. Oral films were 
slightly wet with the help of water. The pH was 
measured by bringing the electrode in contact with the 
surface of the oral film. The experiments were 
performed in triplicate, and average values were 
reported.  
Fourier transformer infrared spectroscopy (FTIR) 
study: 
The compatibility between drug and polymer was 
detected by IR spectra obtained on Shimadzu 8400 
instrument, Japan. The pellets were prepared on KBr-
press (spectra lab, India). The spectra were recorded 
over the wave number range of 4000 to 400 cm
-1
.  
Differential scanning calorimeter (DSC) study: 
Thermograms were obtained by using a differential 
scanning calorimeter (DSC Q20 V24.4 Build 116, 
Japan.) at a heating rate of 10
o
C/min over a temperature 
range of 0-200°C The sample was hermetically sealed 
in an aluminum crucible. Nitrogen gas was purged at 
the rate of 10 ml/min for maintaining inert atmosphere.  
In vitro disintegration time:  
Disintegration test was performed in the USP 
disintegration apparatus. The films were placed in the 
tubes in the container and the disks were placed over it. 
The average disintegration time from each formulation 
was noted in triplicate.  
In vitro dissolution studies of films: 
The prepared fast dissolving films were subjected to in 
vitro dissolution studies using an 8 station USP (Type-
II) dissolution apparatus (Electro Lab, TDT-O8L, 
Mumbai). The dissolution studies were carried out in 
900 ml of 0.1N HCl at 37 ± 0.5
o
C. The speed of the 
paddle was set at 50 rpm. Sampling was done every 1 
min interval up to 10 minutes, there after 5 minutes 
interval up to 30 min and finally at 45, 60 and 90 min 
respectively . For each sample, 5 ml of sample was 
withdrawn from the dissolution medium and replaced 
with equal volume of fresh medium. The samples 
withdrawn were analyzed in the UV spectrophotometer 
at 267 nm.  
Stability studies
14
: 
A stability study of 1 month was carried out for 
optimized batches at 40
o
C±2
o
C and 75%±5% relative 
humidity, 30
o
C±2
o
C and 75%±5% relative humidity. 
After every one month the films were evaluated for 
physical appearance, weight variation, drug content, 
disintegration time and dissolution time.  
RESULTS AND DISCUSSION: 
Phase solubility study of lamotrigine with HP β CD: 
The phase solubility graph for the complex formation 
between lamotrigine and HP β CD is shown in Fig. 1. 
Drug solubility increased with increase in the 
concentration of HP β CD. The slope calculated was 
0.284 which is less than 1, thus 1:1 stoichiometry was 
suggested. The value of the stability constant was found 
to be 470 M
-1
 with high regression value of 0.936 
indicating the formation of instantaneous and high order 
inclusion complexes between the lamotrigine and HP β 
CD
15 and 16
. 
 
Fig: 1 Phase solubility diagram of lamotrigine with 
HP β CD 
Dissolution study of pure drug and inclusion 
complexes:  
In vitro release studies of pure drug and inclusion 
complexes (1:1 and 1:2) were performed using 0.1N 
HCl. The study revealed a significant increase in 
dissolution rate of lamotrigine from the inclusion 
complexes compared to its pure form. Among the three 
different methods, inclusion complexes prepared by 
ultrasonication method exhibited higher rate of 
dissolution compared to the kneading, physical mixture 
and pure drug. Improved dissolution observed in case of 
ultrasonication method may be due to the formation of 
solid inclusion complexes, with better interaction of 
drug and HP β CD during the ultrasonicating process. 
Hence inclusion complexes prepared by ultrasonication 
method (1:1 molar ratio of drug and HP β CD) were 
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utilized in the preparation of fast dissolving films. The results of the dissolution studies are shown in Fig: 2. 
 
 
Fig: 2 In vitro dissolution of pure drug an d inclusion complexes 
Physicochemical characterization of fast dissolving 
films: 
Weight, thickness and drug content of the films: 
The weight of the fast dissolving films were found to be 
uniform from batch to batch and were found to be 
between 59.07 ± 0.05 to 67.59 ± 0.1mg and the 
thickness was varied between 0.154 mm ± 0.001 to 
0.193 mm ± 0.001. The results showed that weight and 
thickness of the films proportionately increased with 
increase in polymer concentration. The low standard 
deviation values ensured the weight and thickness 
uniformity of the prepared films. The drug content in all 
the formulations was found to be between 98.27 ± 0.041 
to 99.70 ± 0.144 %. The results showed that, the drug 
content was uniform and reproducible in each batch of 
different fast dissolving film formulations. 
 
Table: 2 Physicochemical evaluation of fast dissolving films of lamotrigine* 
Code Average 
Weight  
(mg) 
Thickness 
(mm) 
Drug content 
(%) 
Moisture 
absorption 
(%) 
Moisture 
loss (%) 
Folding 
endurance 
Surface pH Disintegration 
time (sec) 
F1 
59.55±0.2 
0.157± 0.002 99.41±0.061 8.71 ± 0.25 10.47±0.49 322.33± 2.51 
6.66 ± 0.15 
24 ± 0.57 
F2 
62.43± 0.11 
0.165± 0.002 98.95±0.328 11.6 ±0.36 8.37±0.33 284.66± 1.52 
6.33±0.11 
26 ± 0.57 
F3 
64.12± 0.05 
0.179± 0.001 98.93±0.371 13.83 ± 0.76 6.45 ± 0.46 257.33± 3.05 
6.63±0.057 
29 ± 1.52 
F4 
60.03± 0.10 
0.157± 0.001 98.76±0.353 9.56 ± 0.44 9.36 ± 0.42 327.33± 1.15 
6.76±0.152 
23 ± 0.57 
F5 
60.37± 0.21 
0.158± 0.001 98.70±0.156 10.83 ±0.75 8.42 ± 0.37 333.66± 2.08 
6.46±0.152 
20 ± 0.57 
F6 
61.03±0.05 
0.157± 0.002 99.13±0.045 12.68 ± 0.27 7.19 ± 0.43 342.33± 3.05 
6.63±0.208 
18 ± 0.57 
F7 
65.09± 0.07 
0.171± 0.001 98.82±0.122 11.65 ± 0.33 8.52 ± 0.28 315.33± 3.05 
6.66±0.208 
16 ± 0.57 
F8 
66.42± 0.20 
0.183± 0.002 99.44±0.120 13.39 ± 0.12 8.06 ±0.06 305.66± 2.51 
6.83±0.057 
13 ± 1 
F9 
67.59± 0.1 
0.193± 0.001 98.27± 0.041 15.60 ± 0.35 7.57±0.26 295.33± 3.05 
6.53±0.208 
17 ± 2 
F10 59.07± 0.05 
0.154± 0.001 ----- 9.83 ± 0.76 6.85 ±0.08 325.66± 1.15 
6.66±0.251 
32 ± 1.15 
F11 65.86±0.09 
0.183± 0.002 ----- 12.68 ± 0.42 8.50 ± 0.16 303.33± 2.08 
6.5±0.3 
18 ± 3.05 
F12 61.20± 0.04 
0.181± 0.001 99.25± 0.092 8.76 ± 0.40 8.53 ±0.19 311.66± 1.52 
6.73±0.057 
14 ± 2 
F13 62.46± 0.07 
0.182±0.003 98.83± 0.087 10.37 ± 0.54 8.29 ±0.06 315.33± 0.57 
6.43±0.152 
16 ±1.52 
F14 63.15±0.06 0.183± 0.001 99.70± 0.144 12.59 ± 0.36 8.22 ± 0.03 321.33± 2.08 6.76±0.057 18 ± 1.15 
*Average of 3 determinations ± SD 
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Percentage moisture absorption and loss: 
The percentage moisture absorption test was carried out 
to check physical stability or integrity of the film at 
humid condition. Among all, the formulations 
containing higher concentration of HPMC and glycerin 
showed greater moisture absorption compared to the 
formulations containing lower concentration of HPMC. 
Glycerin and HPMC both being hydrophilic in nature 
has the tendency to increase the moisture absorption
17
. 
Fast dissolving films containing the PVA along with 
HPMC showed more moisture absorption compared to 
those containing HPMC alone. This could be probable 
be due more hydrophilic nature of PVA than HPMC.  
The percentage moisture loss study was carried out to 
check the integrity of the fast dissolving films at dry 
condition. Percentage moisture loss was inversely 
proportional to the HPMC concentration in the films. 
Also, as the glycerin concentration was reduced, % 
moisture loss was also decreased. It is obvious to note 
that, these hydrophilic excipients tend to hold the 
moisture and their reduced levels in the films may lead 
to higher moisture loss.  
Folding endurance: 
The folding endurance of a film is frequently used to 
estimate the ability of the film to withstand repeated 
bending, folding and creasing and may be encountered 
as a measure of the quality of the films. The folding 
endurance of different fast dissolving films was in the 
range of 257.33 ± 3.05 to 342.33 ± 3.05. Folding 
endurance of HPMC films increased with increase in 
concentration of HPMC and glycerin.
 
This could be due 
to more elasticity of polymer at higher levels of HPMC 
in the films and also as the plasticizer concentration 
increases, flexibility of the film also increases and thus 
the folding endurance too
18
.  
Surface pH determination: 
The prepared films pH should be in the neutral range to 
prevent the irritation and damage to the oral mucosa. 
The surface pH of formulated fast dissolving films was 
found to be in the range of 6.33 to 6.83 which indicates 
that, the formulated fast dissolving films were in the 
neutral pH range and would not cause any irritation 
after placing in the oral cavity.  
 
FT-IR & DSC studies: 
 
Fig: 4 FT-IR spectra of [A] Pure drug lamotrigine, [B] Pure HP ß CD and  [C] Inclusion complexes. 
 
The IR spectrum of the drug lamotrigine exhibited its characteristic absorption bands at 3311 & 3206  for N-H 
stretching of NH2 groups, 3020 for Aromatic C-H stretching, 1615 for C˭˭N stretching, 1550, 1521 and 1485 for C˭˭C 
ring stretching, 1412 & 1317 for C-N stretching, 795 for tri substituted phenyl ring and 747 for C-Cl. 
 
Fig: 5 FT-IR specta of [A] Pure drug lamotrigine, [B] physical mixture of inclusion complex with HPMC, [C] physical 
mixture of inclusion complex with HPMC and  PVA, [D] Optimized formulation (F8) and [E] Optimized formulation (F12) 
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The IR spectra of the physical mixture of drug and HP ß 
CD revealed no significant changes in the absorption 
bands compared to that of pure drug. However, the IR 
of the optimized inclusion complex showed certain 
changes in the absorption bands. It can be interpreted 
that the functional group like NH2 on the ring of the 
drug may interact with OH group of the cyclodextrin 
through hydrogen bonding resulting for the changes in 
the positions of characteristic bands in the spectrum of 
inclusion complex of drug with the cyclodextrin. The IR 
spectra of physical mixtures did not show any 
significant changes in the positions of absorption bands 
when compared to pure drug indicating the 
compatibility of the drug with the excipients used. 
However, some minor and insignificant changes were 
observed in the spectral bands in the IR spectra of the 
optimized formulations and the major peaks remained 
intact suggesting the integrity of the drug. Hence it can 
be concluded that the interaction is due to hydrogen 
bonding between drug and cyclodextrin in the inclusion 
complexes and no chemical interaction in the 
formulations prepared from inclusion complex.
 
 
Fig: 6 DSC thermograms of [A] Pure drug lamotrigine, [B] Inclusion complexes, [C] Optimized formulation (F8) 
and [D] optimized formulation (F12). 
 
The DSC thermogram of pure drug lamotrigine showed 
an intense and significant endothermic peak at 
temperature of 220
o
c which corresponds to the point of 
the drug (214-220
o
c) reported in the literature
19
, thus 
confirming the purity and identity of the drug. 
As observed in Fig: 6(B), the sharp endothermic peak of 
the drug is changed to a very broad endothermic peak in 
the thermogram of drug which is possible only when the 
drug undergoes certain changes like interaction with the 
HP ß CD resulting in the formation of inclusion 
complex. The DSC thermograms of formulation 
containing inclusion complexes with HPMC and 
formulation containing inclusion complexes with HPMC 
and PVA do not show any appreciable significant change 
in the melting point range and nature of the peaks as 
compared with the pure drug and the inclusion complex. 
Overall, the FT-IR and DSC studies conclusively proved 
the integrity of the drug in the pure form and also in its 
different formulations.  
Disintegration time:  
The disintegration times of the films were in the range of 
13 ± 1.0 to 32 ±1 .15 which was largely dependent on the 
various formulation variables. The disintegration time 
was proportionately increased with increase in polymer 
levels in the films, whereas it reduced with increase in 
plasticizer concentration which could be probably due to 
tendency of glycerin to increase the wettability of the 
films. The disintegration time was proportionately 
reduced with increase in superdisintegratant 
concentration only at certain level. Increase in 
superdisintegrant concentration from 4 to 6% could not 
significantly reduce the disintegration time, which could 
be due to blockade of capillary pores preventing the 
entry of fluid in to the films
20
.  The presence of 
cyclodextrin complex also reduced the disintegration 
time of the films compared to those which are prepared 
in absence of the complexes. This could be due to 
hydrophilic nature of the cyclodextrins which resulted in 
reduced disintegration time. Compared to the films 
prepared using HPMC alone, the combination of HPMC 
and PVA films showed lesser disintegration time.  PVA 
being more hydrophilic, its presence in the HPMC films 
resulted in reduced disintegration time
21
. 
In vitro dissolution: 
 
The in vitro disintegration and dissolution are the key 
factors that determine the successful development of fast 
dissolving films. The results of the dissolution study 
revealed that as the polymer concentration in the films 
increased there was a proportionate decrease in drug 
release. This could be due to the extensive swelling of 
the polymer and formation of thick gel structure that 
eventually decreased drug release from the films. It was 
observed that as the plasticizer concentration in the films 
increased there was a proportionate increase in the drug 
release. Glycerin being a hydrophilic excipient and a 
good solubilizer might have increased the drug release. 
Though, the films prepared using higher levels of 
plasticizer though showed better dissolution rate but 
resulted in stickiness of the films. Hence, plasticizer 
concentration of 1%v/v was kept constant. Increase in 
crosspovidone concentration from 2 to 4% has 
significantly increased the drug release from the fast 
dissolving films. However, further increase up to 6% 
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could not significantly increase the drug release. This 
could be probably due to blockade of capillary pores at 
the higher concentration of crosspovidone. The absence 
of inclusion complex (F10) resulted in much slower drug 
release that extended up to 95.62% at the end of 60 min 
dissolution study. However, little improvement in 
dissolution rate was observed in case of formulation F11 
(99.52% in 30 min), which was prepared with pure drug 
but in combination with 4% crosspovidone. Compared to 
the fast dissolving films containing inclusion complexes 
both the above formulations failed to release the drug in 
the shortest possible time. The study revealed that, 
presence of inclusion complexes can significantly 
increase the drug release from the fast dissolving films. 
During the optimization process, films were prepared by 
the combination of HPMC and PVA in different ratios 
(F12 to F14) and their effect on dissolution rate was 
studied. The films containing higher levels of PVA than 
HPMC (F12) resulted in faster dissolution rate (98.77% 
in 6 min) compared to those containing equal (F13, 
99.57% in 8 min) and higher (F14, 96.38% in 8 min) 
amount of HPMC. This could be possibly due to more 
hydrophilic nature of PVA that resulted in improved 
dissolution of the films. In conclusion, the results of 
dissolution study revealed that, formulation variables 
play in important role in the achievement of rapid 
dissolution of the drug from the fast dissolving films.
 
 
Fig: 7 In vitro dissolution profile of fast dissolving films of lamotrigine 
Stability studies: 
The stability studies were carried out for the optimized 
formulations (F8 and F12) at 40±2
o
C/ 75±%5 RH as per 
ICH guidelines for a period of one month and evaluated 
for their physical appearance, weight variation, drug 
content and drug release study. No significant changes in 
the appearance, weight of the fast dissolving films was 
observed during the stability study. The drug content of 
F8 and F12 after stability studies was found98.69±0.19, 
and 99.08±0.18 % respectively. There was no significant 
variation in T50% and T90% at the end of one month 
stability period. This indicated that the fast dissolving 
films remained fairly stable at 40
0
±2 C, 75 % RH.  
CONCLUSION: 
In the present study fast dissolving films of lamotrigine 
were prepared by the incorporation of inclusion 
complexes and the film forming agents like HPMC, PVA 
and other excipients by solvent casting method. The 
prepared films exhibited uniform thickness, weight, drug 
content and rapid disintegration. The incorporation of HP 
ß CD inclusion complexes and superdisintegrants greatly 
improved the drug release from the prepared films. Over 
all the fast dissolving films of lamotrigine were 
successfully prepared and the obtained in vitro results 
were promising for the effective control of epileptic 
seizures in the shortest possible time. 
CONFLICT OF INTEREST: We the authors, do not 
have any personal or financial conflict regarding the 
publication of this manuscript. 
ACKNOWLEDGEMENTS: 
The authors are thankful to M/S Kopalle Pharama 
Pvt.Ltd.Hyderabad and M/S Gangwal Chemicals 
Mumbai for providing pure drug lamotrigine and HP ß 
CD respectively. The authors are also thankful to the 
management of Navodaya Educational Trust, Raichur for 
providing necessary research facilities to carry out the 
present work. 
 
 
 
 
 
 
0
20
40
60
80
100
0 5 10 15 20 25 30
C
u
m
u
la
ti
v
e 
%
 d
ru
g
 r
el
ea
se
Time (min)
F1 F2 F3 F4 F5 F6 F7
Doddayya et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(6):99-106 106 
© 2011-14, JDDT. All Rights Reserved                                                    ISSN: 2250-1177                                            CODEN (USA): JDDTAO 
REFERENCES: 
1. Mohire NC, Yadav AV, “ Novel approach to formulate β-
cyclodextrin complexed mouth dissolving tablet of 
metronidazole and its in-vitro evaluation” Journal of 
Pharmaceutical Research, 2010, 3(3), 662-667. 
2. Mandeep k, Rana A.C, Nimrata S, “Fast Dissolving Films An 
Innovat   Drug Delivery System” International Journal of 
Pharmaceutical Research and Allied Sciences, 2013, 2(1), 14-
24. 
3. Deepak H, Aggarwal G and. Hari Kumar SL, “ Recent trends 
of fast dissolving drug delivery system”  An International 
Research Journal of  Pharmacophore, 2013,  4 (1), 1-9. 
4.  Patil RR, Shende AJ, Devarajan PV,  “Microemulsion of 
lamotrigine for nasal delivery” Indian Journal of 
Pharmaceutical Sciences, 2007, 69(5), 721-722. 
5. Amrutkar PP, Patil SB, Todarwal AN, Wagh MA, Kothawade 
PD, Surawase RK “Design and evaluation of taste masked 
chewable dispersible tablet of lamotrigine by melt 
granulation” International Journal of Drug Delivery, 2010, 2, 
183-191. 
6. Goudanavar P, Shah SH, Hiremath D, “Developement and 
characterization of Lamotrigine orodispersible tablets: 
inclusion complex with hydroxypropyl B cyclodextrin” 
International Journal of Pharmacy and Pharmaceutical 
Sciences, 2011, 3(3), 208-214. 
7. Patil SS, Doddayya H, Gupta VRM, Gupta KS, “Effect of pH, 
selected cyclodextrins and complexation methods on 
solubility of lornoxicam” International Journal of Pharmacy 
and pharmaceutical Sciences, 2014 , 6(8) :,324-327. 
8. Arya A, Chandra A, Sharma V, Pathak K, “Fast Dissolving 
Oral Films: An Innovative Drug Delivery System and Dosage 
Form” International Journal of Chemical Technology and 
Research, 2010, 2(1), 576-583. 
9. Bhupinder B, Sarita J “Formulation and evaluation of fast 
dissolving sublingual films of Rizatriptan Benzoate” 
International Journal of Drug Development and Research, 
2012, 4(1), 133-143. 
10. Shelke PV, Dumbare AS, Godhave MV, Jadhav SL, 
Sonawane AA, Gaikwad DD, “Formulation and evaluation of 
rapidly disintegrating film of amlodipine besylate” 
International Journal of drug delivery & therapeutics, 2012 , 
2(2) , 72-75. 
11. Sabar MH. “Formulation and in vitro evaluation of fast 
dissolving film containing amlodipine besylate solid 
dispersion” International Journal of Pharmacy and 
Pharmaceutical Sciences, 2013, 5(4), 419-428. 
12. EL- Nabarawi MA, Makky AM, EL-Setouhy DA, ABD 
Elmonem RA, Jasti BA “Development and characterization of 
orobuccal film”. International Journal of Pharmacy and 
Pharmaceutical Sciences, 2012, 4(4), 186-193. 
13. Nagar M, Nagar M, Chopra V, “Formulation and evaluation 
of mouth dissolving film of antipsychotic drug aripiprazole” 
Der pharmacia letter, 2012 , 4(4) ,1221-1227. 
14. Jani M, Pandya H, “Formulation and evaluation of fast 
releasing film of odansetron hydrochloride” International 
Journal of Pharmaceutical Sciences 2012, 3(4), 2463-2476. 
15. Bhise SD. Effect of Hydroxypropyl β- Cyclodextrin Inclusion 
Complexation on Solubility of Fenofibrate. International 
Journal of Research in Pharmaceutical and Biomedical 
Sciences, 2011, 2 (2), 596-604. 
16. Ghodke DS, chaulang GM, Patil KS, Nakhat PD, Yeole P G, 
Naikwade NS, Magdum CS, “Solid State Characterization of 
Domperidone: Hydroxypropyl-β-Cyclodextrin Inclusion 
Complex” Indian Journal of Pharmaceutical Sciences, 2010, 
72(2), 245–249. 
17. Nappinnai M, Chandanbala R, Balaijirajan R, “Formulation 
and evaluation of nitrendipine buccal films” Indian Journal of 
Pharmaceutical Sciences, 2008, 70(5), 631-635. 
18. Patil P, Shrivastava SK, “Formulation, evaluation and 
optimization of fast dissolving oral film of selective 
antihypertensive drug” World Journal of pharmacy and 
pharmaceutical Sciences, 2014, 3(8), 996-1060. 
19. Gangavarapu PK, Dr. Prasad GS, “Physicochemical 
Properties of Lamotrigine and its Compatibility with Various 
Inactive Ingredients to Formulate Lamotrigine Orally 
Disintegrating Tablets” International Journal of 
Pharmaceutical and Biological Archives, 2013, 4(1), 94-95. 
20. Patil A, Ghorwade V, Patil S, Ikkurthi K, Inuganti KS, 
Porandla V, “Formulation and evaluation of monteluksat 
sodium fast dissolving films by using gelatin as a film base” 
Research Journal of pharmaceutical, Biological and 
Chemical. Sciences, 2011, 2(3), 880-888. 
21. Chauhan NS, Tomar A, Sharma K, Mittal A, Bajaj U, 
“Formulation and evaluation of fast dissolving oral film of 
dicyclomine as potential route of buccal delivery” 
International.Journal of drug development and Research, 
2012, 4(2), 408-417. 
 
